Pages that link to "Q44685863"
Jump to navigation
Jump to search
The following pages link to Randomized controlled trial comparing docetaxel-cisplatin combination with weekly docetaxel alone in elderly patients with advanced non-small-cell lung cancer: Japan Clinical Oncology Group (JCOG) 0207†. (Q44685863):
Displaying 11 items.
- Highlights for ESMO 40: celebration review for lifetime achievement awards (Q28075787) (← links)
- Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis (Q33401852) (← links)
- Docetaxel versus docetaxel plus cisplatin for non-small-cell lung cancer: a meta-analysis of randomized clinical trials (Q33441413) (← links)
- Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti-PD-1/PD-L1 Antibodies. (Q38920195) (← links)
- xCT expression modulates cisplatin resistance in Tca8113 tongue carcinoma cells (Q42722024) (← links)
- An integrated analysis of hyponatremia in cancer patients receiving platinum-based or nonplatinum-based chemotherapy in clinical trials (JCOG1405-A). (Q49787360) (← links)
- Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy? (Q50240602) (← links)
- Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management. (Q55237828) (← links)
- A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC. (Q64896994) (← links)
- Phase II Study on Biweekly Combination Therapy of Gemcitabine plus Carboplatin for the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer (Q90257593) (← links)
- Geriatric Research Policy: Japan Clinical Oncology Group (JCOG) policy (Q90359207) (← links)